Albireo Pharma Inc (NASDAQ:ALBO) Short Interest Update

Albireo Pharma Inc (NASDAQ:ALBO) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 688,900 shares, a decline of 13.0% from the January 15th total of 791,600 shares. Currently, 6.8% of the company’s shares are short sold. Based on an average daily trading volume, of 77,500 shares, the days-to-cover ratio is presently 8.9 days.

ALBO has been the subject of a number of recent research reports. Cowen reiterated a “buy” rating and set a $39.00 price target on shares of Albireo Pharma in a report on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and set a $62.00 price target on shares of Albireo Pharma in a report on Thursday, January 30th. ValuEngine upgraded shares of Albireo Pharma from a “buy” rating to a “strong-buy” rating in a report on Monday, December 30th. Wedbush reiterated a “buy” rating and set a $69.00 price target on shares of Albireo Pharma in a report on Wednesday, November 6th. Finally, BidaskClub upgraded shares of Albireo Pharma from a “sell” rating to a “hold” rating in a report on Thursday. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $49.00.

In other news, major shareholder Perceptive Advisors Llc purchased 255,809 shares of the stock in a transaction dated Monday, February 3rd. The stock was acquired at an average cost of $21.00 per share, for a total transaction of $5,371,989.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 3.70% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. Citigroup Inc. grew its holdings in Albireo Pharma by 68.0% in the fourth quarter. Citigroup Inc. now owns 2,182 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 883 shares during the period. California State Teachers Retirement System grew its holdings in Albireo Pharma by 6.6% in the third quarter. California State Teachers Retirement System now owns 16,956 shares of the biopharmaceutical company’s stock valued at $339,000 after purchasing an additional 1,057 shares during the period. Bank of New York Mellon Corp grew its holdings in Albireo Pharma by 8.2% in the fourth quarter. Bank of New York Mellon Corp now owns 36,315 shares of the biopharmaceutical company’s stock valued at $923,000 after purchasing an additional 2,750 shares during the period. Marshall Wace North America L.P. purchased a new stake in Albireo Pharma in the fourth quarter valued at approximately $79,000. Finally, Man Group plc grew its holdings in Albireo Pharma by 1.8% in the third quarter. Man Group plc now owns 192,850 shares of the biopharmaceutical company’s stock valued at $3,857,000 after purchasing an additional 3,350 shares during the period. Hedge funds and other institutional investors own 71.25% of the company’s stock.

Albireo Pharma stock opened at $24.74 on Friday. Albireo Pharma has a 1 year low of $16.13 and a 1 year high of $38.69. The firm has a 50 day moving average price of $24.49 and a 200 day moving average price of $22.43. The company has a market cap of $313.24 million, a price-to-earnings ratio of -4.26 and a beta of 1.69.

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Read More: Diversification

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News